Insights into vascular health
Welcome to RetiCAD
A Fast, Objective, and Accurate Retinal Decision Support Tool
RetiCAD
RetiCAD is an AI software support tool for detecting vascular pathology in the retina.
Today, the interpretation of Fluorescein Angiography still requires ophthalmologists to manually inspect the many images generated in each test. This is time-consuming, subjective, and relies on the limited human eye.
RETICAD addresses this technological gap to facilitate reliable identification of patients who can benefit from therapeutic interventions that can limit the development of vision loss.
RetiCAD annotates the 3 disease hallmarks ophthalmologists look for in tests:
Leakage of retinal blood vessels
Aberrant Perfusion (Ischemia)
Lack of blood flow to retinal tissue
*RetiCAD has not yet been cleared for sales
RetiCAD enables ophthalmologists to
analyze tests:
Faster
Objectively
With accuracy beyond the capacity of the naked eye
Using RetiCAD ophthalmologists
can:
See more patients
Measure disease progression in patient follow-ups
Assess the efficacy of treatments
Using RetiCAD pharmaceutical researchers can:
Reduce inter-rater variability in clinical trial readings
Improve quality and efficiency of FA interpretation
Assess the efficacy of treatments
Interested in RetiCAD?
We're Seeking Research and Clinical Trial Partners
Partners and Collaborators
Emagix is working with multiple organizations to further develop and improve its ability to deliver analysis that provides effective assistance to clinicians.
Bionova leads, accelerates, and advocates for Nova Scotia’s growing health and life sciences sector.
.png){kind=logo}
Innovacorp invests in early stage Nova Scotia entrepreneurs, combining venture capital with business mentoring and incubation facilities.
The Atlantic Canada Opportunities Agency (ACOA) works to create opportunities for economic growth in the region by helping businesses.
